You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • THU0088 Structural damage progression in patients treated with methotrexate, baricitinib monotherapy or baricitinib + methotrexate based on their level of clinical response in the phase 3 ra-begin study

Article info

Article menu

Download PDFPDF

Poster Presentations
Rheumatoid arthritis - prognosis, predictors and outcome
THU0088 Structural damage progression in patients treated with methotrexate, baricitinib monotherapy or baricitinib + methotrexate based on their level of clinical response in the phase 3 ra-begin study
Free

Authors

Citation

Heijde DVD, Durez P, Schett G, et al
THU0088 Structural damage progression in patients treated with methotrexate, baricitinib monotherapy or baricitinib + methotrexate based on their level of clinical response in the phase 3 ra-begin study
Annals of the Rheumatic Diseases 2017;76:233.

Publication history

  • First published June 15, 2017.
Online issue publication 
January 09, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions